Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-02T19:05:59.345Z.
Calculation as of: 2026-10-02T19:05:59.345Z.
Quote observation: 2026-10-02T19:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.74B
EBITDA Yield
22.42%
TTM Avg
14.95%
3Y Avg
6.63%
5Y Avg
7.26%
Market Cap
$2.72B
EBITDA Yield
3.79%
TTM Avg
2.98%
3Y Avg
2.17%
5Y Avg
2.17%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 22.42% | 14.95% | 6.63% | 7.26% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 3.79% | 2.98% | 2.17% | 2.17% |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | 8.02% | 4.46% | 2.35% | 2.35% |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | N/A | 1.44% | 5.28% | 7.05% |
| NRC Health (NRC)vs › | $459.30M | 4.28% | 6.59% | 7.36% | 6.54% |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
